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Abstract
To maintain tolerance, autoreactive B cells must regulate signal transduction from the B cell
receptor and Toll-like receptors. We recently identified that dendritic cells and macrophages
regulate autoreactive cells during TLR4 activation by releasing IL-6 and soluble CD40L
(sCD40L). These cytokines selectively repress antibody secretion from autoreactive, but not
antigenically naïve, B cells. How IL-6 and sCD40L repress autoantibody production is unknown.
In this paper, we show that IL-6 and sCD40L are required for low-affinity/avidity autoreactive B
cells to maintain tolerance through a mechanism involving receptor crosstalk between the BCR,
TLR4, and the IL-6 receptor or CD40. We show that acute signaling through IL-6 receptor or
CD40 integrates with chronic BCR-mediated ERK activation to restrict pERK from the nucleus
and repress TLR4-induced Blimp-1 and XBP-1 expression. Tolerance is disrupted in 2-12H/MRL/
lpr mice where IL-6 and sCD40L fail to spatially restrict pERK and fail to repress TLR4-induced
Ig secretion. In the case of CD40, acute signaling in B cells from 2-12H/MRL/lpr mice is intact,
but the chronic activation of pERK emanating from the BCR is attenuated. Re-establishing
chronically active ERK through retroviral expression of constitutively active MEK1 restores
tolerance upon sCD40L, but not IL-6, stimulation indicating that regulation by IL-6 requires
another signaling effector. These data define the molecular basis for the regulation of low-affinity
autoreactive B cells during TLR4 stimulation, they explain how autoreactive but not naïve B cells
are repressed by IL-6 and sCD40L, and they identify B cell defects in lupus-prone mice that lead
to TLR4-induced autoantibody production.
Introduction
Tolerance mechanisms that eliminate or inactivate autoreactive B and T cells prevent
adaptive immune responses to self-antigens. Elimination or inactivation of self-reactive B
cells occurs during development through a series of checkpoints involving receptor editing,
clonal deletion, anergy, and competition for growth factors [1–3]. Additional mechanisms
limit self-antigen presentation, co-stimulation, proliferation, and participation in germinal
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centers[4]. Tolerance mechanisms also regulate autoreactive B cells activated by pathogen
associated molecular patterns (PAMPS) through Toll-like receptors (TLRs) [5–8].
Regulating TLR-induced immunoglobulin (Ig) secretion is important in maintaining
tolerance because gene deletion and overexpression studies have identified TLR2, TLR4,
and TLR7 as contributing to autoantibody titers, renal disease, and the heightened cytokine
production found in autoimmune disease [9–16]. Further, cell surface expression of
endogenous self-antigens such as the TLR4/TLR9 chaperone molecule gp96, promote lupus-
like autoimmune disease in mice [10]. Thus, activation of TLR4by endogenousligands,[17,
18]can potentially activate autoreactive B cells.
Since antigenically naïve and autoreactive B cells express TLRs, maintaining tolerance
requires that B cells acutely stimulated by foreign antigen be regulated differently from
those chronically stimulated by self-antigen. We recently identified dendritic cell (DC)/
macrophage (MF)-mediated tolerance as a mechanism that selectively represses Ig secretion
from autoreactive B cells in response to TLR4 stimulation. We found that IL-6 and sCD40L,
secreted by TLR4-activated DCs and MFs, repress TLR4-induced Ig secretion in
autoreactive B cells, while these soluble mediators fail to repress antigenically naïve B cells
[5, 6]. This finding suggests that acute stimulation of the IL-6 receptor or CD40 in cells
chronically stimulated through the BCR attenuates TLR4 activation.
The molecular mechanisms underlying B cell unresponsiveness rely on chronic binding of
self-antigen to the B cell receptor (BCR) [19]. Mechanistically, constitutive BCR
engagement induces low-level calcium oscillations that sustain continuous ERK activation
through KSR2, a protein scaffold that links the Ca2+ pathway to the Ras/MAPK pathway
[20–23]. This low-level ERK activation has been referred to as tolerogenic ERK [8, 21], and
is insufficient to activate key signaling effectors required for complete B cell activation and
Ig secretion. How chronic low-level ERK activation regulates Ig secretion has not been
defined; however, biological significance is ascribed to changes in ERK activation in other
systems [24]. For example in fibroblasts, sustained but not transient ERK activation leads to
entry into S phase [25]. In the immune system, the amplitude of the ERK response and the
spatial localization of pERK impact the decision between T cell activation and anergy [26,
27]. In the nervous system, sustained ERK activation promotes neuronal cell differentiation
through the stabilization of immediate early gene products such as c-fos [28].
In this report, we show that the ability of DCs and MFs to repress LPS-induced antibody
secretion from autoreactive B cells relies on two ERK signals originating from different
receptors. The first signal is the chronic basal pERK induced by constitutive self-antigen
ligation of the BCR. The second is the acute ERK signal derived from theIL-6 receptor or
CD40. Integration of these two signals excludes pERK from the nucleus and represses
Blimp-1 and XBP-1 expression. We find that in addition to pERK, a second (unidentified)
signaling effector is required for IL-6to regulate TLR4. In contrast, repression by sCD40
requires only pERK. Regulating TLR4 through chronic and acute pERK is important in
disease because IL-6 and sCD40L fail to repress anti-nucleosome production in lupus-prone
MRL/lpr and anti-Sm in 2-12H/MRL/lpr mice. Loss of tolerance is associated with loss of
the high basal pERK (tolerogenic ERK) and coincident with the inability to exclude pERK
from the nucleus despite normal signaling through CD40 and TLR4. This suggests that loss
of tolerogenic ERK by the BCR is at least in part responsible for the loss of tolerance during
TLR4 stimulation. Collectively, the findings illustrate the three-way integration of signals
from the BCR, CD40/ IL-6 receptor and TLR4 that allow autoreactive, but not antigenically
naïve, B cells to be repressed during TLR4-induced immune responses.
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2-12H, 2-12H/Vκ8, 2-12H/MRL/lpr,2-12H/MRL/MpJ, MRL/lprand Ars/A1 transgenic mice
have been previously described [19, 29–32]. C57BL/6 (B6), MD4 (HEL-Ig), and MD4 ×
ML5 (HEL-Ig × sHEL) mice were purchased from The Jackson Laboratory. Female 2-12H/
MRL/lpr, 2-12H/MRL/MpJ, and MRL/lprmice were used at 5–9 weeks of age. All other
mice were 8 to 14 weeks of age at the time of analysis. Animals were maintained in an
accredited animal facility at the University of North Carolina.
Reagents
Hen egg lysozyme (HEL) and double-stranded DNA (dsDNA) were purchased from Sigma.
dsDNA was boiled and rapidly chilled to make single-stranded DNA (ssDNA). p-
azophenylarsonate conjugated to BSA (Ars5BSA) was provided by Larry Wysocki (National
Jewish Research Center, Denver, CO). Small nuclear riboprotein (snRNP) complexes were
purified from HeLa cells as previously described [33]. Fluorochrome- or biotin-labeled
antibodies specific for CD3 (145-2C11), CD9 (KMC8), CD11b (Ml/70), CD11c (HL3),
CD19 (1D3), CD21 (7G6), CD23 (B3B4), CD138 (281-2), and B220 (RA3-6B2) were
purchased from BD Bioscience, phospho-p44/42 MAPK (T202/Y204) from Cell Signaling,
and goat anti-rabbit IgG-Alexa 647 from Molecular Probes. Recombinant IL-6 (rIL-6) was
purchased from eBioscience, and recombinant soluble CD40L (rsCD40L) from R&D
Systems. HB100 (anti-IgMa/κ), 187.1 (anti-κ),RS3.1 (anti-IgMa), 33-60 (anti-IgM), B7.6
(anti-IgM), and 2.4G2 (anti-CD16/32) were purified from hybridoma culture supernatant
using Protein G Sepharose (GE Healthcare), or MEP HyperCel (BioSepra). The MEK1
inhibitors U0126 and PD98059 were purchased from Calbiochem (San Diego, CA),
resuspended in DMSO, and used at 0.5 µM (U0126) and 20 µM (PD98059).
B cell purification
Splenic B cells were isolated by negative selection (StemCell Technologies). B cells were
70–95% pure (with fewer than 5% DCs and MFs). In some experiments, marginal zone B
cells were depleted from B6 splenocytes by the addition of biotinylated anti-CD9. Ficoll-
Paque PLUS (GE biosciences) separation was used prior to negative selection to increase the
purity of B cells from MRL/lpr, and 2-12H/MRL/lpr mice.
Retroviral transduction of B cells
Dr. Harvey Lodish (Whitehead Institute) and Dr. Chris Marshall (Institute of Cancer
Research, London, UK) provided constitutively active MEK1 (CA-MEK1) and dominant
negative MEK1 (DN-MEK1), respectively. These cDNA constructs were subcloned into
MSCV-LTR. The retroviral constructs were transfected into Plat-E ecotropic packaging cells
(Cellbiolabs) and cultured for 48 hrs. Supernatants were harvested and stored at −80°C. To
express DN-MEK1 and CA-MEK1, we LPS-stimulated B cells for 18 hours in the absence
or presence of rIL-6 or rsCD40L. Cells were washed and viral supernatants (1ml) were
added with polybrene (5µg/ml) for 2 hours then washed and re-cultured with LPS in the
absence or presence of rIL-6 or rsCD40L. GFP expression was evident by 24 hours but cells
were cultured 48 hours before Ig secretion was measured. The efficiency of retroviral
transduction ranged from 15%(2-12H/MRL/lpr) to 50–65% (B6 and 2-12H/Vκ8).
Cell sorting
Follicular (FO; CD19+CD23+CD21/35loCD138−), marginal zone (MZ;
CD19+CD23−CD21/35+CD138−), and pre-plasma cells (pre-PC; CD19+CD138int) were
sorted from 2-12H and 2-12H/MRL/lpr mice (>90% purity). GFPhi cells were sorted from
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CA-MEK-transduced B cells on day 4 (> 98% purity), and from DN-MEK1-transduced B
cells on day 2 (> 98% purity).
LPS stimulation
Purified B cells (1 × 105/per well) were cultured with LPS from E. coli 055:B5 (Sigma; 30
µg/ml) or purified LPS (Invitrogen; 15 µg/ml) for 4 days in the absence or presence of rIL-6
(30 ng/ml), rsCD40L (75 ng/ml), HEL (100 µg/ml), ssDNA (500 ng/ml), Ars5BSA (2 µg/
ml), Sm (50 U/ml), or snRNP (50 µg/ml). The different sources of LPS (Sigma or
Invitrogen) did not yield different results in any assay but simply reflect availability.
Immunoglobulin secretion was measured by ELISA from cell-free culture supernatants.
ELISPOT Assays
Since allelic exclusion is >93% in the 2-12H/Vκ8 (H+L restricted) B cells we used ELISA
analysis (IgMa/κ) to quantitate Ig secretion [5, 29].To detect antibody from 2-12H B cells
(no light chain restriction), we used ELISPOT to ensure that only Sm-specific antibody
secreting cells (ASCs) were enumerated [6]. For ELISPOT analysis, cells were cultured for
3 days (or for retroviral infection, sorted for GFP expression, then cultured for 3 days),
washed and transferred to plates coated with 1 U/well Sm antigen (Immunovision) and
incubated for 8 hrs. The ASCs were detected using biotinylated anti-IgMa followed by
streptavidin-horseradish peroxidase (BD Biosciences). The plates were analyzed using an
ImmunoSpot Analyzer and software package (Cellular Technology).
ELISA
IgM secretion by B6 mice was detected using anti-mouse IgM (33–60) and biotin-labeled
anti-mouse IgM (B7.6). IgMa/κ ELISA was used to measure IgM secretion by Ars/A1 mice.
Mouse anti-HEL (IgMa) (MD4 × ML5) was measured as described previously [5,
34].Mouse anti-Sm (IgMa) was detected using anti-mouse IgMa (RS3.1) and biotinylated
anti-mouse IgM (B7.6). Mouse anti-nucleosome Ig was capturedon plates coated overnight
at 4°C with mouse histones(4 µg/well; Immunovision). Plates were washed and blocked
with BSA containing dsDNA (10 µg/ml Sigma-Aldrich) for 3 h at room temperature.
Samples and standards (PL2-6) were loaded and incubated overnight at 4°C then detected
with biotinylated goat anti-mouse Ig. PL2-6 (anti-nucleosome hybridoma) was used to
generate a standard curve.
Real-time PCR
Total RNA was extracted from 2 × 106 B cells using TRIZOL (Invitrogen). cDNA was
prepared with random hexamers and M-MLV reverse transcriptase (Invitrogen) andanalyzed
in triplicate real-time PCR reactions. Primers for xbp-1 were as follows: (forward, 5'-
ACACGCTTGGGAATGGACAC -3';reverse, 5' CCATGGGAAGATGTTCTGGG -3').
Primers for prdm1 (Blimp-1) and 18s RNA have been described [35, 36]. Quantitative PCR
(SYBR Green) reactions were performed on an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems).Quantification of transcripts relative to 18s RNA transcripts
was determined using the ΔΔ Ct method [37].
Immunoblotting
Cell lysates were prepared from 3 × 106 cells in buffer containing 1% NP-40, 150 mM
NaCl, 10 mM Tris (pH 7.5), 2 mM sodium orthovanadate, 1 mM PMSF, 0.4 mM EDTA, 10
mM NaF, and 1 µg/ml each of aprotinin, leupeptin, and α1-anti-trypsin (Sigma). SDS-
PAGE separated proteins were immunoblotted for phospho-ERK and total ERK (Cell
Signaling Technologies), Blimp-1 (Novus Biologicals), XBP-1, lamin A, or β-tubulin (Santa
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Cruz Biotechnology, Inc). Proteins were detected using chemiluminescence (GE
Biosciences).
Nuclear and cytoplasmic extracts
Purified splenic B cells were stimulated with LPS alone or in combination with rIL-6 or
rsCD40L for 30 minutes. To collect cytoplasmic extracts, 15 × 106 cells were resuspended
in 200 µl lysis buffer (10 mM HEPES (pH 7.9), 10 mM MgCl2, 0.5 mM DTT, protease and
phosphatase inhibitors[38, 39]) for 15 minutes on ice followed by 5 minute centrifugation at
6600 × g. To collect nuclear extracts, nuclei were washed (as above) then resuspended in 10
µl of buffer D (20 mM HEPES (pH 7.9), 430 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2,
0.5 mM DTT, 25% glycerol, protease and phosphatase inhibitors). After gentle mixing, 50
µl of buffer C (20 mM HEPES (pH 7.9), 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT,
25% glycerol, protease and phosphatase inhibitors) was added and incubated for 15 minutes
at 4°C, then supernatant was collected following centrifugation. Protein concentrations were
determined by the Bradford method (Bio-Rad). Cytoplasmic (5µg) and nuclear (10 µg)
extracts were separated by SDS-PAGE and immunoblotted as above with phospho-ERK,
total ERK, lamin A, and beta-tubulin.
Intracellular phospho-flow
Phosphorylated and total protein levels were determined by flow cytometry as previously
described[40]. Briefly, splenic B cells were purified by negative selection and stimulated
with LPS in the absence or presence of rIL-6 or rsCD40L for various time points. At
indicated times, cells were fixed with 2 % PFA for 15 min, permeabilized for 30 min on ice
with cold MeOH, washed with PBS containing 2%FCS, and then FcR blocked with mAb
2.4G2 (10 µg/ml) for 15 min. Cells were stained with anti-phospho-ERK(p44/42) or anti-
ERK(p44/42) (Cell signaling Technology) for 1hr, washed 3 times then stained with CD19
(BioLegend) and F(ab')2 fragment of goat anti-rabbit IgG (H+L) (Invitrogen) for 1hr. ERK
phosphorylation levels were determined by flow cytometry.
Confocal Microscopy
B cells purified by negative selection were fixed in 2% PFA (room temperature, 15
minutes), permeabilized in ice-cold methanol (10 minutes at −20°C), and then blocked in
2.4G2 for 1 hr. Cells were stained with Hoechst 33342 (1 µg/ml; 15 minutes at room
temperature), washed, and stained for pERK (1 hr) followed by goat anti-rabbit IgG-Alexa
647 (1 hr). Images were captured using a Zeiss 710 confocal microscope with a 63 × 1.4 NA
(oil) PLAN APO lens and Zeiss Zen software. Randomly chosen cells were analyzed in
Image J. The nuclear localization of pERK was quantified by calculating the Mander’s
coefficient of colocalization (ratio of colocalized pixels/total fluorescent pixels) between red
and blue fluorescence (ratio=50%, threshold red=50, threshold blue=30).
Statistical Analysis
The one-sample t test was used when comparing antibody secretion in treated and untreated
cultures and for the quantitation of confocal microscopy data. The exact Wilcoxon rank-sum
test was used to compare antibody secretion between experimental groups. Statistical
analyses were performed with GraphPad Prism.
Results
Smith (Sm) antigen fails to regulate TLR4-induced Ig secretion
Regulating TLR-induced Ig secretion by autoreactive B cells is important in maintaining
tolerance. Studies using hen egg lysosyme (HEL)-specific BCR transgenic mice showed that
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binding of high-affinity HEL to B cells from HEL-Ig × sHEL (MD4 × ML5) mice repressed
TLR4- and TLR9-induced Ig secretion [8, 41]. Using a lower affinity model in which B cells
were specific for Smith (Sm) antigen (2-12H/Vκ8), we showed that DC/MF-derived IL-6
and sCD40L repressed TLR4-induced Ig secretion [5, 6]. To assess whether repression of Ig
secretion from lower affinity B cells was regulated in the same way as HEL-specific B cells,
we cultured HEL-, Ars- and Sm-specific B cells with their cognate antigens and LPS (Figure
1A). We included Ars/A1 B cells because the Ars-specific BCR allowed us to directly
compare a low affinity nuclear self-antigen (ssDNA) to a higher avidity multivalent neo-
self-antigen (Ars5BSA). Consistent with previous findings[5], LPS stimulation of unpurified
splenocytes from HEL-, Ars-, and Sm-specific immunoglobulin transgenic mice showed
markedly reduced Ig secretion due to the presence of DCs and MFs. Upon separation of the
B cells from DC/MFs, LPS-stimulated B cells from all of the models lost their unresponsive
phenotype and secreted Ig (Figure 1A). Co-culture of anergic HEL-specific B cells (sHEL ×
HEL-Ig) with soluble HEL repressed LPS-induced Ig secretion, as previously shown [41].
The co-culture of Ars-specific B cells with Ars5BSA reduced Ig secretion by 90%, while
ssDNA repressed 38% of secretion (Figure 1A, middle panel). In contrast, neither
recombinant Sm nor snRNPs repressed Ig secretion from 2-12H/Vκ8 B cells (Figure 1A,
right panel). These data indicate that chronic BCR exposure to HEL and Ars5BSA confers
TLR4 unresponsiveness, and suggests that low-affinity/avidity nuclear self-antigens only
partially modulate (ssDNA), or fail to modulate(Sm/snRNPs) TLR4-induced activation.
However, low-affinity antigens are sufficient to induce susceptibility of autoreactive B cells
to repression mediated by IL-6 and sCD40L, soluble factors delivered by TLR4-activated
DCs and MFs [5, 6]. Thus, BCR ligation is important in regulating TLR4-induced
autoantibody production either by directly regulating TLR4, or by indirectly impacting
TLR4 through IL-6 receptor and CD40.
To determine whether the repression of TLR4-induced Ig secretion by IL-6 and sCD40L
was unique to B cells from immunoglobulin transgenic mice, we tested whether these
soluble mediators repressed nucleosome-specific B cells from C57BL/6 (B6) mice. As
shown in Figure 1B (left panel), recombinant IL-6 (rIL-6) repressed 41%, while
recombinant soluble CD40L (rsCD40L) repressed 34%, of anti-nucleosome secretion.
Diminished Ig secretion was specific to autoreactive cells because neither rIL-6 nor
rsCD40L significantly repressed total IgM (Figure 1B, right panel). Collectively, the data
show that IL-6 and sCD40L repress transgenic and non-transgenic B cells of multiple
autoreactive specificities, and in contrast to the direct regulation of TLR4 by high-affinity
antigens, low-affinity antigens require the products of activated DCs and MFs.
rIL-6 and rsCD40L regulate transcription factors involved in plasma cell differentiation
To establish the molecular basis for the repression of autoreactive B cells by IL-6 and
sCD40L, we examined whether the transcription factors that promote plasma cell
differentiation are repressed by rIL-6 or rsCD40L. Blimp-1 represses Bcl-6, Pax5, and c-
myc while promoting Ig secretion by upregulating XBP-1.When Sm-specific B cells were
LPS-stimulated in the presence of rIL-6 or rsCD40L, prdm1 (Blimp-1) message levels were
reduced by approximately 50% (Figure 2A, upper panel). rIL-6 and rsCD40L also reduced
Blimp-1 protein levels by 60% and 80% respectively (Figure 2A, lower panel). Similarly,
rIL-6 reduced the message levels of XBP-1 by 70% in LPS-stimulated Sm-specific B cells,
while rsCD40L reduced message levels by 64% (Figure 2B, upper panel). rIL-6 and
rsCD40L also repressed XBP-1 protein levels by 70% and 80%, respectively (Figure 2B,
lower panel). This indicates that when B cells are chronically exposed to self-antigen, IL-6
and sCD40L interfere with the TLR4-induced transcriptional program that directs plasma
cell differentiation.
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2-12H/Vκ8 B cells exhibit heightened levels of basal pERK
Compared to naïve B cells, autoreactive cells exhibit increased basal ERK phosphorylation
(tolerogenic ERK) [19, 21, 22]. To begin to understand how IL-6 and sCD40L regulate
TLR4-induced Ig secretion we assessed whether low-affinity Sm-specific B cells (2-12H/
Vκ8) exhibit heightened basal phospho-ERK (pERK). As shown in Figure 3A, 2-12H/Vκ8
B cells (anergic) exhibited a 6.9-fold higher level of basal ERK phosphorylation compared
to B6 B cells (naïve). When compared in side-by-side analysis, these levels were
comparable to those found in B cells from HEL-Ig × sHEL mice (data not shown). This
suggests that heightened basal pERK may be important in the regulation of 2-12H/Vκ8 B
cells.
The ability of rIL-6 and rsCD40L to repress TLR4-induced Ig is ERK-dependent
Since constitutive ERK phosphorylation is central to anergy [21–23], we sought to
determine whether rIL-6 and rsCD40L regulate TLR4-induced Ig secretion via pERK. We
treated LPS-stimulated 2-12H/Vκ8 B cells with U0126, a pharmacological inhibitor of
MEK1 (Figure 3B). We found that when ERK activation was inhibited, rIL-6 was unable to
repress TLR4-induced Igsecretion and sCD40L repressed only 25% of Ig secretion. To
corroborate these results, we used retroviral gene transfer to introduce DN-MEK1 into
2-12H/Vκ8 B cells (Figure 3C). When cells were transduced with DN-MEK1, rIL-6 only
repressed 37% of Ig secretion, while it repressed 52% of Ig secretion in LPS-stimulated
2-12H/Vκ8B cells. Although not statistically different (ρ=0.07), we consistently saw that
cells expressing DN-MEK had higher Ig secretion. In contrast, DN-MEK1 expressing2-12H/
Vκ8 B cells were not repressed by rsCD40L, and actually showed enhanced Ig secretion
(165% of controls). This enhanced secretion reflected B cell proliferation (data not shown).
It remained unclear why U0126 had a much greater effect on IL-6 mediated repression than
did DN-MEK1.To ensure that the ability of U0126 to restore Ig secretion during IL-6
costimulation was not due to non-specific effects, we assessed whether PD98059 restored Ig
secretion (supplemental Figure 1). Like U0126, LPS stimulated 2-12H/Vκ8 B cells
costimulated with IL-6 in the presence of PD98059 restored Ig secretion suggesting that the
MEK/ERK pathway plays a role in the regulation of Ig secretion by IL-6. Taken together,
these results indicate that repression of TLR4-induced Ig secretion by sCD40L, and likely
IL-6, is dependent on ERK activation.
Regulation of TLR4-induced Ig secretion by rIL-6 and rsCD40L does not alter the
magnitude or kinetics of ERK phosphorylation
In most signal transduction pathways, the activation of ERK occurs rapidly (within 10
minutes) and is not sustained. However, in anergic B cells the low-level Ca2+ oscillations
occurring as a consequence of constitutive self-antigen ligation of the BCR promote a low
level of continuously active ERK. Thus, when other ERK-coupled surface receptors, such as
IL-6R and CD40 become activated, the acute ERK signal they induce is superimposed on
the chronic, sustained pERK emanating from the BCR. To begin to understand how IL-6
and sCD40L repress TLR4-induced Ig secretion, we used flow cytometry to assess whether
they promoted altered patterns of ERK phosphorylation over time. As shown in Figure 3D,
the levels of pERK increased slightly during the first 12 hours of LPS stimulation but were
substantially increased between 12 and 18 hours. It is noteworthy that LPS-stimulated B6 B
cells (Figure 3E) achieved higher levels of pERK by 18 hours that increased by 72 hours,
while pERK in 2-12H/Vκ8 B cells plateaued after 12 hours. Regardless, these levels were
not significantly altered by treatment with rIL-6 or rsCD40L in B6 or 2-12H/Vκ8 mice. The
levels of total ERK were also not different between B6 and 2-12H/Vκ8 B cells, and total
ERK increased over time in both groups (Figure 3F and 3G). Similarly, immunoblotting did
not detect changes in pERK upon IL-6 or rsCD40L costimulation (data not shown).Thus, the
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ability of IL-6 and sCD40L to repress LPS-induced Ig secretion cannot be explained by
changes in ERK phosphorylation.
rIL-6 and rsCD40L alter the subcellular localization of pERK in 2-12H/Vκ8 B cells
In addition to phosphorylation, ERK can be regulated by subcellular location. Spatial
restriction of pERK has been shown to contribute to T cell activation while a diffuse
distribution of pERK is associated with anergy [26, 27, 42]. To test whether rIL-6
orrsCD40L altered the intracellular location of pERK, we analyzed cells by confocal
microscopy. We found that unstimulated B6 B cells retained pERK in the cytoplasm, but
upon LPS stimulation, pERK was translocated to the nucleus within 1 hour (Figure 4A and
compilation in 4C). The location of pERK in the nucleus did not change when LPS-
stimulated B6 B cells were treated with rIL-6 or rsCD40L. Similar to the unstimulated B6 B
cells, unstimulated 2-12H/Vκ8 B cells retained pERK in the cytoplasm and upon LPS
stimulation, translocated pERK to the nucleus (Figure 4B and compilation in 4C). However,
treatment of the 2-12H/Vκ8 cells for 1 hour with either LPS+rIL-6, or LPS+rsCD40L
excluded pERK from the nucleus coincident with failure to secrete Ig. Over time (18 hr), the
intensity of pERK staining diminished and the remaining pERK entered the nucleus of
2-12H/Vκ8 B cells. Except for aunique punctate staining in the cytoplasm of 2-12H/Vκ8 B
cells, the distribution of pERK was similar in B6 and 2-12H/Vκ8 B cells (supplemental
Figure 2A, 2B, and compilation in 2C). By day 3 (when early Ig secretion is detected) both
B6 and 2-12H/Vκ8 B cells once again showed strong pERK staining; however, it was
restricted to the nucleus regardless of treatment with rIL-6 or rsCD40L (supplemental Figure
2D, 2E, and compilation in 2F).
To corroborate this finding, we prepared B cell nuclear extracts (lamin A+; β-tubulin-) from
B6 and 2-12H/Vκ8 mice B cells (supplemental Figure 3). Stimulation with LPS increased
nuclear pERK in both B6 and 2-12H/Vκ8 B cells. However, treatment with LPS+rIL-6 or
LPS+rsCD40L reduced the levels of nuclear pERK in 2-12H/Vκ8 B cells, but not B6 B
cells. Collectively, the data show that within 1 hour following co-stimulation of IL-6
receptor or CD40 in combination with TLR4, pERK is excluded from the nucleus of
autoreactive B cells coincident with the repression of Ig secretion.
rIL-6 and rsCD40L fail to repress Sm-specific B cells from 2-12H/MRL/lpr mice
Our findings that DC/MF-mediated tolerance regulates autoreactive B cells during TLR4
stimulation identify a potential point of dysregulation in lupus-prone mice. We reasoned that
a B cell defect that disrupted chronic BCR ligation might prevent the heightened levels of
basal pERK and/or attenuate the spatial restriction of pERK, thereby allowing autoantibody
secretion. To test this possibility, we co-cultured 2-12H and 2-12H/MRL/lpr B cells with
LPS in the absence or presence of rIL-6 or rsCD40L (Figure 5A). As expected, rIL-6 and
rsCD40L repressed Ig secretion from 2-12H B cells(58% and 50%, respectively). However,
B cells from 2-12H/MRL/lpr mice were significantly less repressed by rIL-6 and rsCD40L
(39% and 27%, respectively). This is not due to Fas deficiency because rIL-6 and rsCD40L
were unable to repress B cells from 2-12H/MRL/MpJ mice (Figure 5C). To ensure that the
failure to regulate autoreactive B cells in the 2-12H/MRL/lprmice was not unique to the
2-12H transgene, we tested whether nucleosome-specific B cells in MRL/lpr mice were
regulated by IL-6 and sCD40L during TLR4 responses. As shown in Figure 5B, neither
rIL-6 nor rsCD40L repressed anti-nucleosome Igin MRL/lpr mice. Coincident with the loss
of regulation of Ig secretion, rIL-6 and rsCD40L did not diminish LPS-induced Blimp-1 and
XBP-1 levels (Figure 5D). This reveals that the regulatory mechanisms controlling TRL4-
induced Ig secretion are disrupted in lupus-prone mice.
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The inability of rIL-6 and rsCD40L to repress Ig secretion is coincident with loss of basal
pERK, and the translocation of pERK to the nucleus
Our data show that Sm-specific B cells exhibit heightened levels of basal ERK
phosphorylation, and upon co-stimulation with rsCD40L or rIL-6, they exclude pERK from
the nucleus. To determine whether basal ERK phosphorylation was lost when tolerance was
overcome in the 2-12H/MRL/lpr model, we compared basal pERK levels from B6, 2-12H,
and 2-12H/MRL/lpr mice (Figure 5E). We found that like 2-12H/Vκ8 B cells, those from
2-12H mice exhibited heightened levels of pERK consistent with an anergic phenotype [45].
However, the levels of pERK in B cells from 2-12H/MRL/lpr mice were reduced to levels
seen in B6 B cells.
To assess whether loss of tolerance in lupus-prone mice was associated with the entry of
pERK into the nucleus, we stimulated B cells from 2-12H/MRL/lpr mice with LPS, LPS
+rIL-6, or LPS+rsCD40L for 1 hour, 18 hours, or three days, then assessed the subcellular
location of pERK by confocal microscopy. We found that at 1 hour, B cells from 2-12H/
MRL/lpr mice stimulated with LPS, LPS+rIL-6, or LPS+rsCD40L failed to exclude pERK
from the nucleus, a phenotype much like that seen with stimulated B6 B cells (Figure 5 F
and G). Over time, lower levels of pERK were found in both the nucleus and cytoplasm of
2-12H/MRL/lpr B cells, with a punctate cytoplasmic staining pattern at 18 hours
(supplemental Figure 4A and 4B), and a punctate nuclear stain by day 3 (supplemental
Figure 4C and 4D). Surprisingly, at day 3, rIL-6 or rsCD40L treated cells from 2-12H/MRL/
lpr mice once again trended toward excluding pERK from the nucleus (supplemental Figure
4D). Taken together, the data in Figures 4A/B and 5F show that repression of TLR4-induced
Ig by rIL-6 or rsCD40L is coincident with exclusion of pERK from the nucleus. However
when tolerance is overcome, TLR4 stimulation induces the translocation of pERK to the
nucleus despite co-stimulation by rIL-6 or rsCD40L. This indicates that in autoreactive B
cells, loss of susceptibility to IL-6 and sCD40L occurs coincident with loss of tolerogenic
pERK, the failure to exclude pERK from the nucleus, and the inability to decrease the levels
of Blimp-1 and XBP-1.
Inducing active MEK restores the ability of sCD40L to repress TLR4-induced Ig secretion
The data show that ERK activation is critical for sustaining anergy during TLR4-induced
innate responses. Thus, we reasoned that if the loss of ERK phosphorylation caused the loss
of susceptibility to IL-6 and sCD40L in lupus-prone B cells, restoring pERK through a gain-
of-function approach might restore tolerance. To address this, we used retroviral gene
transfer to express GFP-tagged constitutively active-MEK1 (CA-MEK1) in 2-12H/MRL/lpr
B cells. We found that sorted CA-MEK1-expressing 2-12H/MRL/lpr B cells treated with
rsCD40L repressed 54% of Ig secretion (Figure 6A); a level comparable to that found in
2-12H B cells treated with rsCD40L (Figure 5A). Surprisingly, Ig secretion from 2-12H/
MRL/lpr B cells treated with rIL-6 was not repressed despite the expression of MEK (Figure
6A). This suggests that a second signaling effector is required for IL-6 to repress TLR4-
induced Ig secretion. Ideally, defining the subcellular location of pERK in ex vivorsCD40L-
treated B cells expressing CA-MEK1 would allow us to assess the role of spatial restriction.
However, the inducible spatial restriction of pERK seen at 1 hour is not observed after the
unavoidable delay (~18-24 hrs) needed to activate B cells and retrovirally infect them (see
supplemental Figure 4A). Regardless, the data indicate that the regulation of TLR4-induced
Ig secretion by rIL-6 requires pERK and another signaling effector(s), while pERK is
sufficient for rsCD40L to repress autoantibody production.
High basal pERK is essential for CD40-mediated repression of Sm-specific B cells
Our findings point to a central role for ERK in CD40L and IL-6 mediated repression of Sm-
specific B cells. However, ERK is activated by multiple receptors including BCR (basal
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tolerogenic pERK), TLR4, and CD40/IL-6 receptor. Which is responsible for repressive
pERK is unknown. Our findings in Figure 5 indicate that IL-6 andsCD40L fail to repress
activation of Sm-specific B cells from 2-12H/MRL/lpr mice, and they lack the high basal
pERK characteristic of anergy. This implicates basal pERK coming from chronic BCR
signaling as essential for sCD40L and IL-6 to repress TLR4-induced Ig secretion. To further
test this possibility, we assessed whether ERK activation through the other two receptors
(TLR4 and IL-6 receptor/CD40) was intact. As shown in Figure 6B,the levels of pERK in
B6 and 2-12H/MRL/lpr B cells remained low until 18 hours following LPS stimulation, then
increased between 18 and 72 hours (Figure 6B left panel). Although LPS-stimulated B cells
from B6 mice achieved slightly higher levels of pERK compared to B cells from 2-12H/
MRL/lpr micethe levels of total ERK were also slightly higher in B6 B cells(Figure 6B right
panel). This indicates that following TLR4 stimulation, the magnitude and kinetics of pERK
activation is not different between B6 and 2-12H/MRL/lpr B cells.
We hypothesized that sincesCD40L is solely dependent on pERK to regulate TLR4-induced
Ig secretion, determining whether CD40-mediated signal transduction activates ERK might
allow us to identify the source of pERK that is dysregulated in the 2-12H/MRL/lpr model.
To assess this, we stimulated2-12H/MRL/lpr B cells with rsCD40L over a 1 hour time
course. This timing was chosen because it represents the timeframe when pERK was
excluded from the nucleus in the 2-12H/Vκ8 cells (Figure 4B).We found that rsCD40L
induced phosphorylation of pERK in 2-12H/MRL/lprto a level that was comparable to that
found in B6 (Figure 6C left panel).Since TLR4- and CD40L-induced ERK activation is
normal in 2-12H/MRL/lpr B cells, the data suggest that loss of heightened basal pERK
(tolerogenic pERK) from the BCR prevents sCD40L from repressing TLR4-induced
autoantibody secretion in these autoreactive B cells. However, we cannot exclude the
possibility that pERK induced by TLR4 and CD40 is also essential for CD40-mediated
repression.
Discussion
The ability of autoreactive B cells to regulate TLR-induced activation is essential in
maintaining tolerance to self, as many self-antigens and pathogen-associated antigens bind
TLR4, TLR7, or TLR9 [44]. Our study implicates a central role for BCR activation in
directing the outcome of TLR4-induced Ig responses. We show that B cells expressing high
affinity BCRs efficiently repress TLR4-induced Ig secretion through a B cell intrinsic
mechanism, whereas cells expressing low affinity BCRs utilize a cell extrinsic mechanism.
The cell extrinsic mechanism involves DC- and MF-secreted IL-6 and sCD40L, which
blocks the nuclear translocation of pERK, prevents the expression of Blimp-1 and XBP-1,
and there by terminates plasma cell differentiation (Figure 7). This regulatory mechanism
fails in autoreactive B cells from autoimmune-prone MRL/lpr mice, explaining the
susceptibility of these cells to activation during TLR4-induced innate immune responses.
Cross-regulation of receptor signaling is emerging as a critical mechanism for cells to
achieve specific outcomes [45, 46]. For example, nucleic acid-containing immune
complexes simultaneously stimulate B cells, MFs, and DCs through either FcγRs or BCR
along with TLR7 or TLR9 [13, 15, 47]. Linked activation results in inflammatory cytokine
production or antibody production. Another example is activation of ITAM-containing
receptors and TLRs by ligands that are not physically linked. For example, DAP12 signaling
via TREM-1 synergizes with TLR4 to increase cytokine production [48]. Our studies of
TLR4 activation on autoreactive B cells are consistent with these examples and involve
three receptors, the BCR, IL-6 receptor or CD40, and TLR4. The BCR is an ITAM-
containing receptor that orchestrates TLR4 regulation. Like other autoreactive cells [21, 22],
the chronic binding of self-antigen to Sm-specific BCR selevates the basal level of activated
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ERK likely through low-level Ca2+ oscillations and KSR2, a protein scaffold that links the
Ca2+ pathway to the Ras/MAPK pathway [20–23]. However, high basal pERK levels, or
tolerogenic ERK, are not sufficient to confer unresponsiveness by low affinity Sm-specific
and ssDNA-specific (Ars/A1) B cells as it does for high affinity HEL-specific cells (Figure
1). This is consistent with our previous observations that in the absence of DCs and MFs, the
affinity of the BCR for Sm directly correlates with impairment of TLR4-induced Ig
secretion [49].
Our data indicate that Blimp-1 and XBP-1 are repressed when Sm-specific B cells are TLR4
stimulated in the presence of IL-6 or sCD40L (Figure 2) and this level of regulation is lost in
autoreactive B cells from lupus-prone mice (Figure 5). Thus, the point where chronic pERK,
and acute IL-6R/CD40 signaling intersect TLR4 could be at the level of Blimp-1 up-
regulation. Blimp-1 expression is ERK-dependent, supporting this possibility[50].
Alternatively, the point of intersection may be upstream of Blimp-1. The unique
spatiotemporal pattern of pERK in autoreactive B cells may impact immediate early gene
(IEG) products such as c-Fos, Egr-1, Elk-1, and Myc, which in turn affect Blimp-1
transcription. In support of this idea, others have shown that transient ERK activation
degrades IEG products, while sustained ERK activation induces their prolonged expression
[28, 51, 52]. It is noteworthy that we find nuclear exclusion of pERK 1 hour after
stimulation, but by 18hours post-stimulation pERK is present in the nucleus of Sm-specific
B cells (Figure 4 and supplemental Figure 2). This is more consistent with an indirect effect
of pERK on Blimp-1 expression.
TLR4 stimulation of B cells from B6 and 2-12H/Vκ8 mice translocates pERK to the
nucleus; however, translocation is blocked in Sm-specific cells by an acute signal from
IL-6R or CD40 (Figure 4). The importance of spatially regulating pERK in anergic B cells is
evident from our analysis of autoimmune-prone MRL/lpr mice where TLR4 stimulation fails
to exclude pERK from the nucleus and induces anti-Sm and anti-nucleosome secretion,
regardless of acute IL-6 receptor and CD40 signaling. Coincident with these events, we find
that the heightened basal pERK levels associated with B cell anergy are not evident.
Moreover, CA-MEK restores the ability of at least sCD40L to block pERK nuclear
translocation and antibody production in response to LPS. Thus, high basal pERK is central
in repressing the TLR4-inducedactivation of low affinity Sm-specific B cells.
It is unclear which receptor(s) provides the signal to exclude pERK from the nucleus, since
the BCR, IL-6R/CD40, and TLR4 activate ERK. Our analysis of 2-12H/MRL/lpr B cells
provides some insight into this question. The high basal level of pERK associated with
anergic B cells is absent in these cells (Figure 5), but the acute pERK activation induced by
CD40 and LPS is not different between B cells from 2-12H/MRL/lpr and B6 mice (Figure
6). Since pERK is not excluded from the nucleus in autoreactive B cells from 2-12H/MRL/
lpr mice (Figure 5), we propose that the high basal pERK generated by the BCR is essential
for directing the outcome of acute CD40 signaling, although we do not exclude a role for
pERK generated by other receptors. Whether IL-6 receptor signaling functions in the same
way remains unclear since CA-MEK fails to restore IL-6 mediated repression in B cells
from 2-12H/MRL/lpr mice. pERK appears to play a role in regulating TLR4 through IL-6
receptor since U0126 and PD98059 block IL-6 from repressing TLR4 activation in 2-12H/
Vκ8 B cells; however, the effect by DN-MEK was not significant. Since these MEK/ERK
inhibitors have few off-target effects at the concentrations used [53], we believe the
difference could reflect the inability of DN-MEK to inhibit the activation of endogenous
basal pERK although the exact reason remains unknown. Nonetheless, there is likely
another effector molecule that is important for IL-6 to repress TLR4-induced Ig secretion.
One possibility is STAT3, since recent studies have shown that both pERK and pSTAT3 are
required for Blimp-1 expression [50] and both are activated by the IL-6 receptor [54]. In
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support of this possibility, we have found that pharmacologically inhibiting JAK2/STAT3
attenuates the ability of IL-6 to repress Ig secretion from Sm-specific B cells (unpublished
observation). Our data support a model in which heightened basal pERK is essential for
regulating TLR4 and suggest that, despite continued presence of self-antigen in MRL/lpr
mice, the loss of tolerogenic pERK prevents the regulation of Sm-specific B cells during
TLR4 stimulation.
One possible mechanism that might account for the loss of tolerogenic pERK in MRL/lpr
mice is renewed signaling through the BCR. In anergic B cells, chronic antigen stimulation
leads to the activation of inhibitory pathways that limit subsequent BCR responses. Studies
show that complement-opsonized cross-reactive antigens can overcome B cell anergy and
renew BCR signaling[55, 56].Another possibility is that higher avidity forms of self-antigen,
such as those displayed on the surface of apoptotic debris [57, 58], might attenuate the
chronic tolerogenic ERK signal and renew signal transduction [22].In support of this, we
have found that 2-12H B cells exposed to Sm-containing apoptotic debris renew BCR-
mediated signal transduction. Further, B cells from mice that fail to clear apoptotic debris
(2-12H/Vκ8/MerTKkd) are not repressed by rIL-6 or rsCD40L during TLR4 stimulation,
and they do not exhibit elevated basal pERK (unpublished observations).
In summary, we have identified cross-regulation of the BCR, TLR, and IL-6 receptor/CD40
pathways, possibly through nuclear exclusion of pERK, as a mechanism to regulateTLR4-
induced plasma cell differentiation of low affinity autoreactive B cells. High basal pERK is
required for IL-6 and sCD40L to induce nuclear exclusion of pERK. This is lost in B cells
from autoimmune MRL/lpr mice providing an explanation for why sCD40L is unable to
repress TLR4 activation and leads to the uncontrolled production of anti-nucleosome and
anti-Sm. Thus, B cell tolerance is essential when either LPS or endogenous self-antigens
ligate TLR4, and defects in the mechanism described here contributes to the autoimmune
phenotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Low-affinity/avidity antigens fail to regulate TLR-induced Ig secretion
Splenic B cells (1 × 105) from MD4 × ML5 (A, left panel), Ars/A1 (A, middle panel), and
2-12H/Vκ8 (A, right panel) mice were stimulated for 4 days with LPS (30 µg/ml) in the
absence or presence of HEL (100 µg/ml), ssDNA (500 ng/ml), Ars5BSA (2 µg/ml), Sm (50
U/ml), snRNP (50 µg/ml). IgM or IgMa/κ antibody levels were quantitated by ELISA. In the
LPS-stimulated controls, 100% reflects Ig in the range of 8–16 µg/ml (MD4 × ML5), 2–5µg/
ml (Ars/A1), and 2–3 µg/ml (2-12H/Vκ8). Splenic B cells (1 × 105) from B6 mice (B) were
stimulated for 4 days with LPS (30 µg/ml) in the absence or presence of rIL-6 (30 ng/ml), or
rsCD40L (75 ng/ml). Anti-nucleosome Igand total IgM levels were quantitated by ELISA.
In the LPS-stimulated controls, 100% reflects 18–42 µg/ml anti-nucleosome Ig, and 14–44
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µg/ml total IgM. The data shown represent at least 3 experiments.(*** P<0.001, **P<0.01,
ND: no difference)
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Figure 2. IL-6 and sCD40L decrease the levels of Blimp-1 and XBP-1
2-12H/Vκ8 B cells were stimulated for 3 days with LPS (30 µg/ml) or LPS combined with
rIL-6 (30 ng/ml) or rsCD40L (75 ng/ml). The relative levels of Blimp-1 (A; upper left) and
XBP-1 (B; upper right) message were measured by real-time PCR (**P–0.01, *P<0.05).
2-12H/Vκ8 B cells were cultured for 3 days with LPS or LPS combined with rIL-6 or
rsCD40L. Lysates from 3 × 106 cells were immunoblotted for Blimp-1 (A; lower left) and
XBP-1 (B; lower right).The density of each band was quantitated using Image J, and the fold
changes were calculated relative to β-tubulin. The data shown represent at least 3
experiments.
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Figure 3. IL-6 and sCD40L repress TLR4-induced Ig in a MEK-dependent manner
3 × 106 purified ex vivo B6 and 2-12H/Vκ8 B cells were lysed and immunoblotted for
pERK and total ERK1/2. The density of each band was quantitated with ImageJ, and the
ratio of pERK to total ERK1/2 was calculated and expressed as fold change (A). 2-12H/Vκ8
B cells were stimulated for 4 days with LPS or LPS combined with rIL-6 or rsCD40L, in the
absence or presence of U0126 (0.5 µM)(B). 3 × 106 splenic B cells from 2-12H/Vκ8 mice
were stimulated with LPS (30 µg/ml) in the absence or presence of rIL-6 (30 ng/ml)or
rsCD40L (75 ng/ml) for 18–24 hrs followed by DN-MEK1 gene transfer. Two days later,
GFP+ B cells (1 × 105) were sorted and stimulated under the same conditions for an
additional 48 hrs. IgMa/κ was quantitated by ELISA (C). 1 × 106 splenic B cells from B6 (E
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and G), or 2-12H/Vκ8 (D and F) mice were stimulated with LPS (30 µg/ml) in the absence
or presence of rIL-6 or rsCD40L for various time periods followed by FACS analysis of
intracellular pERK and total ERK staining. The data shown represent at least 3 experiments.
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Figure 4. IL-6 and sCD40L alter the subcellular localization of pERK in B cells chronically
exposed to self-antigen
1 × 106 purified B6 and 2-12H/Vκ8 B cells were stimulated with LPS (30 µg/ml) or LPS in
combination with rIL-6 (30 ng/ml) or rsCD40L (75 ng/ml) for 1 hr. Cells were fixed, stained
for pERK (red) and dsDNA (blue), and imaged using confocal microscopy (A,B). The co-
localization of pERK with the nucleus was quantified in 37–92 cells by calculating the
Mander’s coefficient between red and blue fluorescence (Ratio=50%, Threshold Red = 50,
Threshold Blue = 30) (C).
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Figure 5. IL-6 and sCD40L fail to repress B cells from autoimmune-prone mice
1 × 105 splenic B cells from 2-12H and 2-12H/MRL/lpr mice (5–9 weeks old) were
stimulated with LPS (30 µg/ml) in the absence or presence of rIL-6 (30ng/ml) orrsCD40L
(75 ng/ml) for 4 days. ASCs were enumerated using ELISPOT assays (A). 1 × 105 splenic B
cells from MRL/lpr mice (5–10 weeks old) were stimulated with LPS in the absence or
presence of rIL-6 orrsCD40L for 4days. Anti-nucleosome Ig secretion was quantitated by
ELISA (B). 1 × 105 splenic B cells from 2-12H/MRL/MpJ (2-12H/MRL)mice (5 –9 weeks
old) were stimulated with LPS in the absence or presence of rIL-6 orrsCD40L for 4days.
The number of Sm secreting cells was quantitated by ELISPOT (C). 2-12H/MRL/lpr B cells
were stimulated for 3 days with LPS (30 µg/ml) in the absence or presence of rIL-6 (30 ng/
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ml), or rsCD40L (75 ng/ml). Lysates from 3 × 106 cells were immunoblotted for Blimp-1
and XBP-1. The density of each band was quantitated with ImageJ, and the fold change was
calculated relative to β-actin (D). 3 × 106 purified B6, 2-12H/Vκ8,and 2-12H/MRL/lpr B
cells were lysed and immunoblotted for pERK and total ERK1/2. The density of each band
was quantitated with ImageJ and the ratio of pERK/ERK from 3 experiments was calculated
(E). 1 × 106 purified ex vivo2-12H/MRL/lpr B cells were stimulated with LPS in the
absence or presence of rIL-6 orrsCD40L for 1 hr. Cells were fixed, stained for pERK (red)
and dsDNA (blue), and imaged using confocal microscopy (F). Colocalization of pERK
with the nucleus at the 1 hr time point was quantified in 40 cells by calculating the Mander’s
coefficient between red and blue fluorescence (Ratio=50%, Threshold Red = 50, Threshold
Blue = 30) (G). The data shown represent at least 3 experiments.
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Figure 6. Expression of constitutively active MEK1 restores the ability of sCD40L to repress
TLR4-induced Ig secretion
3 × 106 splenic B cells from 2-12H/MRL/lprmice were stimulated with LPS (30 µg/ml) in
the absence or presence of rIL-6 (30 ng/ml)or rsCD40L (75 ng/ml) for 18 – 24 hr followed
by CA-MEK1 gene transfer. On day 4, GFP+ B cells were sorted and ASCs were
enumerated using ELISPOT assays. Data represent at least 3 experiments. (*P<0.05; ND not
different). 1 × 106 splenic B cells from B6 or 2-12H/MRL/lpr mice were stimulated with
LPS for various time periods followed by intracellular staining with pERK (B, left panel)
and total ERK1/2 (B, right panel). 1 × 106 splenic B cells from B6, and 2-12H/MRL/lpr
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mice were stimulated with rsCD40L (75 ng/ml) for various time periods followed by FACS
analysis of intracellular pERK (C, left panel)and total ERK staining (C, right panel).
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Figure 7. Receptor cross-talk regulates autoreactive B cells during TLR4 stimulation
We propose a model wherein the chronic ligation of self-antigen by the BCR distinguishes
autoreactive B cells from antigenically naïve cells. Chronic BCR ligation induces
chronically active ERK (Figure 3A). In addition to stimulating B cells, LPS induces DCs
and MFs to secrete IL-6 and sCD40L, which in turn acutely stimulateIL-6 receptor or CD40
on B cells inducing an acute pERK signal (Figure 6B for CD40). The combined chronic and
acute ERK signals exclude pERK from the nucleus, limiting expression of TLR4-induced
Blimp-1 and XBP-1 and thereby repressing plasma cell differentiation. Stimulation through
IL-6 receptor relies on pERK (Figure 3), but pERK is not sufficient (Figure 6). The identity
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of the second effector coupled to IL-6 receptor remains unknown, as denoted by the question
mark.
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